Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).
Kinos S, Hagman H, Halonen P, Soveri LM, O'Reilly M, Pfeiffer P, Frödin JE, Sorbye H, Heervä E, Liposits G, Kallio R, Ålgars A, Ristamäki R, Salminen T, Bärlund M, Shah CH, McDermott R, Röckert R, Flygare P, Kwakman J, Teske A, Punt C, Glimelius B, Österlund P. Kinos S, et al. Among authors: osterlund p. Acta Oncol. 2024 May 2;63:248-258. doi: 10.2340/1651-226X.2024.24023. Acta Oncol. 2024. PMID: 38698698 Free PMC article.
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman JJM, Frödin JE, Shah CH, Sorbye H, Ristamäki R, Halonen P, Soveri LM, Heervä E, Ålgars A, Bärlund M, Hagman H, McDermott R, O'Reilly M, Röckert R, Liposits G, Kallio R, Flygare P, Teske AJ, van Werkhoven E, Punt CJA, Glimelius B. Osterlund P, et al. ESMO Open. 2022 Jun;7(3):100427. doi: 10.1016/j.esmoop.2022.100427. Epub 2022 Mar 30. ESMO Open. 2022. PMID: 35798468 Free PMC article.
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Punt CJA, Heinemann V, Maughan T, Cremolini C, Van Cutsem E, McDermott R, Bodoky G, André T, Osterlund P, Teske AJ, Pfeiffer P. Punt CJA, et al. Among authors: osterlund p. ESMO Open. 2023 Apr;8(2):101199. doi: 10.1016/j.esmoop.2023.101199. Epub 2023 Apr 3. ESMO Open. 2023. PMID: 37018874 Free PMC article.
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM. Guren TK, et al. Among authors: osterlund p. Br J Cancer. 2017 May 9;116(10):1271-1278. doi: 10.1038/bjc.2017.93. Epub 2017 Apr 11. Br J Cancer. 2017. PMID: 28399112 Free PMC article. Clinical Trial.
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB, Österlund P, Berglund Å, Glimelius B, Qvortrup C, Sorbye H, Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Research (AgeCare). Winther SB, et al. Among authors: osterlund p. BMC Cancer. 2017 Aug 16;17(1):548. doi: 10.1186/s12885-017-3526-8. BMC Cancer. 2017. PMID: 28814275 Free PMC article. Clinical Trial.
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ, Ryg J, Osterlund P, Berglund Å, Qvortrup C, Glimelius B, Sorbye H, Pfeiffer P. Winther SB, et al. Among authors: osterlund p. Lancet Gastroenterol Hepatol. 2019 May;4(5):376-388. doi: 10.1016/S2468-1253(19)30041-X. Epub 2019 Mar 7. Lancet Gastroenterol Hepatol. 2019. PMID: 30852136 Clinical Trial.
An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer.
Heervä E, Väliaho V, Salminen T, Nieminen L, Carpelan A, Kurki S, Sundström J, Huhtinen H, Rantala A, Carpén O, Minn H, Österlund P, Ålgars A, Ristamäki R. Heervä E, et al. Among authors: osterlund p. Acta Oncol. 2020 Dec;59(12):1503-1507. doi: 10.1080/0284186X.2020.1831062. Epub 2020 Oct 12. Acta Oncol. 2020. PMID: 33044880 Free article. No abstract available.
151 results